ライフサイエンスコーパス: ICRF-187

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 ecan, irinotecan, etoposide and dexrazoxane (ICRF-187).

2 ic CEM cells were selected for resistance to ICRF-187.

3 cities appear to be unaffected by the use of ICRF-187.

4 ven as an intravenous bolus) with or without ICRF-187.

5 ne and complexed with the bisdioxopiperazine ICRF-187.

6 tingly, resveratrol is chemically similar to ICRF-187, a clinically approved chemotherapeutic that st

7 Second, ICRF-187, a Top2 catalytic inhibitor known to deplete To

8 The ternary drug-bound complex reveals that ICRF-187 acts by an unusual mechanism of inhibition in w

9 Dexrazoxane [(DZR), ADR 529, ICRF-187] ameliorates doxorubicin (DOX)-induced cardioto

10 I alpha was essential for rapid dynamics, as ICRF-187, an inhibitor of topoII alpha, blocked recovery

11 We examined cell killing by ICRF-187 and ICRF-193 in yeast cells expressing human to

12 alpha in yeast cells sensitizes them to both ICRF-187 and ICRF-193, compared with cells expressing ye

13 amaging catalytic Topo II inhibitors such as ICRF-187 and merbarone do not do this.

14 analysis of the biochemical effects of both ICRF-187 and resveratrol on the human isoforms of topo I

15 e approximately 40- and 69-fold resistant to ICRF-187, and 12- and 67-fold cross-resistant to ICRF-19

16 ind that resveratrol indeed acts through the ICRF-187 binding locus, but that it inhibits topo II by

17 The topo II-specific inhibitor ICRF-187 blocks this effect, indicating that it is cause

18 marked contrast, when treated with equitoxic ICRF-187 doses, the drug-resistant clones exhibit either

19 Dexrazoxane (Zinecard, also known as ICRF-187) has been used in the clinic as a cardioprotect

20 In summary, resistance to ICRF-187 in CEM cells is associated with increased level

21 ICRF-187 is a bisdioxopiperazine anticancer drug that in

22 However, the killing caused by ICRF-193 and ICRF-187 is not enhanced by mutations in the RAD52 pathw

23 ICRF-187 reduces the risk of developing short-term subcl

24 topoIIalpha transcriptional up-regulation in ICRF-187-resistant cells is mediated in part by altered

25 The ICRF-187-resistant clones contain approximately 5-fold i

26 ptional regulation in ICRF-187-sensitive and ICRF-187-resistant human leukemic cell lines that expres

27 ed topoIIalpha transcriptional regulation in ICRF-187-sensitive and ICRF-187-resistant human leukemic

28 Finally, the catalytic Topo II inhibitor ICRF-187 suppressed VM-26-induced-FasL expression.

29 Eighteen ICRF-187-treated and 15 control patients were assessable

30 ICRF-187-treated patients had a significantly higher inc

31 ICRF-187-treated patients were less likely to develop su

32 the short-term cardioprotection afforded by ICRF-187 will reduce the incidence of late cardiac compl

33 label, randomized trial to determine whether ICRF-187 would reduce doxorubicin-induced cardiotoxicity

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。